Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Why This Pharma Stock More Than Doubled Today
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen to buy Apellis Pharmaceuticals for $5.6 billion